# A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia

> **NCT00249145** · PHASE3 · COMPLETED · sponsor: **Janssen Pharmaceutica N.V., Belgium** · enrollment: 349 (actual)

## Conditions studied

- Dementia
- Alzheimer Disease
- Dementia, Vascular

## Interventions

- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00249145
- **Lead sponsor:** Janssen Pharmaceutica N.V., Belgium
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-04
- **Primary completion:** —
- **Final completion:** 1996-12
- **Target enrollment:** 349 (ACTUAL)
- **Last updated:** 2011-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00249145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00249145, "A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00249145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*